Table 2.
Mean (sd) change from baseline in DTSQ scores (ITT)† to end of week 26
| DTSQs | DTSQc | |||||
|---|---|---|---|---|---|---|
| Item | Liraglutide | Exenatide | Relative difference between treatments (95% CI; P-value*) | Liraglutide | Exenatide | Relative difference between treatments (95% CI; P-value*) |
| Current treatment | ||||||
| Baseline | 4.4 (1.7) (n = 188) | 4.6 (1.4) (n = 187) | ||||
| Change from baseline | 1.01 (1.99) (n = 179) | 0.49 (1.82) (n = 172) | 0.37 (0.09–0.65; 0.009) | 2.72 (0.69) (n = 164) | 2.39 (0.93) (n = 144) | 0.35 (0.17–0.53; 0.0002) |
| Convenience | ||||||
| Baseline | 4.8 (1.3) (n = 187) | 4.7 (1.2) (n = 187) | ||||
| Change from baseline | 0.59 (1.51) (n = 179) | 0.02 (1.75) (n = 174) | 0.68 (0.41–0.92; < 0.0001) | 2.47 (0.98) (n = 164) | 2.10 (1.28) (n = 144) | 0.40 (0.15–0.66; 0.002) |
| Flexibility | ||||||
| Baseline | 4.5 (1.6) (n = 187) | 4.4 (1.5) (n = 187) | ||||
| Change from baseline | 0.70 (1.80) (n = 179) | 0.19 (1.85) (n = 175) | 0.57 (0.27–0.86; 0.0002) | 2.30 (1.05) (n = 163) | 1.93 (1.34) (n = 144) | 0.38 (0.12–0.64; 0.005) |
| Understanding | ||||||
| Baseline | 4.6 (1.3) (n = 188) | 4.6 (1.3) (n = 187) | ||||
| Change from baseline | 0.49 (1.19) (n = 179) | 0.38 (1.52) (n = 174) | 0.14 (−0.09 to 0.36; 0.236) | 2.36 (0.85) (n = 163) | 2.33 (0.91) (n = 144) | 0.02 (−0.17 to 0.21; 0.828) |
| Recommend | ||||||
| Baseline | 4.6 (1.6) (n = 186) | 4.8 (1.4) (n = 185) | ||||
| Change from baseline | 0.96 (1.64) (n = 178) | 0.35 (1.85) (n = 170) | 0.49 (0.23–0.75; 0.0003) | 2.67 (0.90) (n = 163) | 2.41 (1.02) (n = 143) | 0.28 (0.06–0.50; 0.012) |
| Continue | ||||||
| Baseline | 4.4 (1.8) (n = 186) | 4.5 (1.7) (n = 186) | ||||
| Change from baseline | 1.03 (2.25) (n = 178) | 0.25 (2.35) (n = 173) | 0.66 (0.33–0.99; 0.0001) | 2.71 (0.74) (n = 163) | 2.32 (1.14) (n = 143) | 0.40 (0.19–0.62; 0.0003) |
| Perceived hyperglycaemia | ||||||
| Baseline | 3.8 (1.8) (n = 185) | 3.8 (1.8) (n = 186) | ||||
| Change from baseline | −1.82 (2.16) (n = 176) | −1.61 (2.29) (n = 174) | −0.27 (−0.63 to 0.09; 0.142) | −0.99 (1.86) (n = 163) | −0.33 (1.93) (n = 145) | −0.74 (−1.17 to −0.31; 0.0007) |
| Perceived hypoglycaemia | ||||||
| Baseline | 1.0 (1.5) (n = 187) | 0.9 (1.4) (n = 186) | ||||
| Change from baseline | 0.06 (2.02) (n = 179) | 0.11 (1.69) (n = 173) | −0.02 (−0.32 to 0.29; 0.908) | −0.88 (1.78) (n = 164) | −0.44 (1.80) (n = 145) | −0.48 (−0.89 to −0.08; 0.019) |
*
Versus exenatide group.
†
DTSQs scores were evaluated by LOCF methodology; DTSQc scores were analysed in the per-protocol population.
DTSQc, Diabetes Treatment Satisfaction Questionnaire change version; DTSQs, Diabetes Treatment Satisfaction Questionnaire status version; ITT, intention to treat; LOCF, last observation carried forward.